5.1 Immune Mechanisms, Hypersensitivity Reactions, and Autoimmune Disease Testing

Immune Mechanisms, Hypersensitivity Reactions, and Autoimmunity

Quick Answer: Understanding immunology for the medical laboratory requires a strong grasp of how the immune system can malfunction. This includes the four types of Gell and Coombs hypersensitivity reactions and the precise interpretation of autoantibody patterns, particularly Antinuclear Antibodies (ANA), used to diagnose systemic autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).

The immune system is an intricate network designed to defend the body against exogenous pathogens. However, immune dysregulation can lead to inappropriate responses, either overreacting to environmental antigens (hypersensitivity) or failing to recognize self-antigens (autoimmunity). Laboratory professionals play a pivotal role in identifying the serological footprints of these derangements.

Gell and Coombs Hypersensitivity Reactions

The Gell and Coombs classification divides hypersensitivity reactions into four distinct types based on the underlying immune mechanisms and the timeline of the response. Types I, II, and III are antibody-mediated (humoral), while Type IV is cell-mediated.

Type I: Immediate (IgE-Mediated) Hypersensitivity

Type I hypersensitivity is characterized by an immediate allergic reaction occurring within minutes of antigen re-exposure. It is mediated by IgE antibodies bound to the high-affinity Fc receptors (FcεRI) on mast cells and basophils.

• Mechanism: Upon subsequent exposure, the allergen cross-links the bound IgE molecules, triggering rapid degranulation. This releases preformed vasoactive mediators like histamine, followed by newly synthesized lipid mediators (leukotrienes, prostaglandins).
• Clinical Manifestations: Anaphylaxis, allergic asthma, allergic rhinitis (hay fever), and food allergies.
• Laboratory Testing: Total serum IgE levels (RIST), allergen-specific IgE testing (RAST or fluorescent enzyme immunoassays), and in vivo skin prick testing.

Type II: Cytotoxic (Antibody-Mediated) Hypersensitivity

Type II hypersensitivity involves IgG or IgM antibodies directed against antigens present on the surface of cells or extracellular matrix components.

• Mechanism: Antibody binding leads to cell destruction via three main pathways: classical complement pathway activation (causing MAC-mediated lysis), antibody-dependent cellular cytotoxicity (ADCC) by NK cells or macrophages, or opsonization leading to phagocytosis.
• Clinical Manifestations: Hemolytic Transfusion Reactions (HTR), Hemolytic Disease of the Newborn (HDN), Autoimmune Hemolytic Anemia (AIHA), and Goodpasture syndrome (anti-GBM antibodies).
• Laboratory Testing: Direct Antiglobulin Test (DAT) or Direct Coombs test to detect in vivo coating of RBCs with antibody or complement.

Type III: Immune Complex-Mediated Hypersensitivity

Type III hypersensitivity is driven by the formation of soluble antigen-antibody (IgG/IgM) immune complexes in the circulation that evade phagocytic clearance.

• Mechanism: These complexes deposit in vascular beds (especially in the kidneys, joints, and skin), activating the classical complement cascade. This generates anaphylatoxins (C3a, C5a) that recruit neutrophils. The neutrophils release lysosomal enzymes and reactive oxygen species, causing severe tissue damage.
• Clinical Manifestations: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Post-streptococcal glomerulonephritis, and Serum sickness.
• Laboratory Testing: Complement levels (C3, C4) are characteristically decreased during active disease flares due to consumption. Detection of specific autoantibodies (e.g., ANA) is also essential.

Type IV: Delayed (Cell-Mediated) Hypersensitivity

Unlike the first three types, Type IV does not involve antibodies. It is mediated by antigen-specific T cells (CD4+ Th1 cells and CD8+ cytotoxic T cells) and macrophages. The reaction typically peaks 48-72 hours after antigen exposure.

• Mechanism: Th1 cells secrete cytokines (such as IFN-gamma) that activate macrophages, leading to localized inflammation and tissue damage. If chronic, this can result in granuloma formation.
• Clinical Manifestations: Contact dermatitis (e.g., poison ivy, nickel allergy), Tuberculin skin test (PPD) reaction, Multiple Sclerosis, and Type 1 Diabetes Mellitus.
• Laboratory Testing: T-cell functional assays (e.g., QuantiFERON-TB Gold for interferon-gamma release).

---

Autoimmune Disease Testing

Autoimmune diseases occur when central or peripheral tolerance fails, leading to an adaptive immune response against self-antigens. The cornerstone of autoimmune diagnostics is the detection of specific autoantibodies.

Antinuclear Antibodies (ANA) and Immunofluorescence

The standard screening test for systemic autoimmune rheumatic diseases is the Antinuclear Antibody (ANA) test, primarily performed using Indirect Immunofluorescence Assay (IFA) on HEp-2 cells (Human Epithelioma type 2). The resulting fluorescent pattern and titer provide critical diagnostic clues.

Note: A positive ANA is highly sensitive for SLE (>95%) but has poor specificity, as low titers can be found in healthy individuals and the elderly.

Systemic Lupus Erythematosus (SLE)

SLE is a quintessential systemic autoimmune disease characterized by immune complex deposition (Type III hypersensitivity). While ANA is the screening test, specific antibodies are required for confirmation:

• Anti-dsDNA (double-stranded DNA): Highly specific for SLE. Titers correlate directly with disease activity and the risk of lupus nephritis.
• Anti-Smith (Anti-Sm): Highly specific for SLE but only present in ~30% of patients. Does not correlate with disease activity.
• Anti-Histone: The hallmark autoantibody of Drug-Induced Lupus Erythematosus (DILE), triggered by medications like procainamide or hydralazine.

Rheumatoid Arthritis (RA)

RA is a chronic, systemic inflammatory disorder that primarily affects the synovial joints.

• Rheumatoid Factor (RF): An autoantibody, most commonly an IgM class, directed against the Fc portion of host IgG. While sensitive, RF is not specific and can be positive in other autoimmune diseases or chronic infections.
• Anti-Cyclic Citrullinated Peptide (Anti-CCP): Extremely specific (~95%) for Rheumatoid Arthritis. It often appears early in the disease process, predicting a more erosive joint disease course.

Other Organ-Specific Autoantibodies

• Hashimoto's Thyroiditis: Anti-Thyroid Peroxidase (Anti-TPO) and Anti-Thyroglobulin (Anti-Tg).
• Graves' Disease: Thyroid-stimulating immunoglobulin (TSI) or TSH receptor antibodies (TRAb).
• Celiac Disease: Tissue Transglutaminase IgA (tTG-IgA) and Endomysial Antibody (EMA-IgA). Total IgA levels must be checked to rule out selective IgA deficiency, which could cause false-negative serology.
• Primary Biliary Cholangitis (PBC): Anti-Mitochondrial Antibodies (AMA).

---

Clinical Application and Exam Strategy

For the AMT MLS exam, you must be able to link the pathophysiological mechanism (e.g., immune complex deposition) to the disease (SLE) and to the corresponding laboratory findings (decreased C3/C4, homogeneous ANA, positive anti-dsDNA). Pay close attention to the distinction between sensitivity (ANA screening) and specificity (anti-dsDNA/anti-Sm for confirmation). Additionally, always remember the specific molecular targets of autoantibodies, such as RF targeting the Fc region of IgG, which is a classic board exam distractor.